AbCellera Biologics Inc. 8-K Report: Corporate Changes Unveiled

Based on the provided XML section of a financial report, here are the key pieces of information extracted:
- Entity Information:
- Name: AbCellera Biologics Inc.
- CIK (Central Index Key): 0001703057
- SEC File Number: 001-39781
- Industry: Biologics (implied by the name)
- Report Type:
- Form: 8-K (which is used to report unscheduled material events or corporate changes)
- Reporting Date:
- Date of Report: February 18, 2025
- Address:
- Current Address: 150 W 4th Avenue, Vancouver, BC, V5Y 1G6
- Former Address: 2215 Yukon Street, Vancouver, BC
- Contact Information:
- Phone Number: (604) 559-9005
- Security Information:
- Common Shares Ticker: ABCL
- Exchange: NASDAQ
- Context IDs:
- Context ID 1 (c-1): Refers to the main reporting period of February 18, 2025.
- Context ID 2 (c-2): Also refers to the same reporting period for the former address.
Insights:
- The filing is an 8-K, indicating that AbCellera Biologics Inc. is likely disclosing significant information to investors or regulators on February 18, 2025.
- The change in address could suggest a relocation or a significant operational change within the company, which may impact its business operations or strategic direction.
- The entity is listed on NASDAQ under the ticker ABCL, which provides insight into its public trading status and market presence in the biotechnology sector.
- The presence of a former address suggests that the company has undergone changes, which could be relevant for stakeholders or investors monitoring organizational stability or growth.
Conclusion:
The section reveals important corporate changes for AbCellera Biologics Inc., specifically a change in address and the filing of an 8-K on February 18, 2025, which may be significant for investors and analysts monitoring the company. Further details in the full report would be necessary to understand the context of these changes fully.